Pricing
  1. JP-listed companies
  2. Linical Co., Ltd.
  3. Financials
  4. EBITDA margin (%)

Linical Co., Ltd.【JP:2183】

Market cap
¥6.9B
P/E ratio
-3.7x
Linical helps pharmaceutical companies develop and launch new drugs by providing clinical trial services, post-market safety monitoring, and drug discovery support.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA margin (%) YoY (%)
Mar 31, 2025-4-155.19%
Mar 31, 20247.3-36.59%
Mar 31, 202311.5+5.81%
Mar 31, 202210.9+72.15%
Mar 31, 20216.3-41.67%
Mar 31, 202010.8-8.83%
Mar 31, 201911.9-44.75%
Mar 31, 201821.5-19.36%
Mar 31, 201726.6-2.83%
Mar 31, 201627.4+47.00%
Mar 31, 201518.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)